---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Antibody-Drug conjugates"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Antibody-Drug conjugates. Topics: Antibody-drug conjugate recommendations in third-line treatment and beyond: ESMO 2026 guideline, Antibody-drug conjugate positioning and sequencing: ABC8 consensus 2026, Trastuzumab deruxtecan for HER2-low disease: ASCO 2022 rapid recommendation update, Sacituzumab govitecan for hormone receptor-positive disease: ASCO 2023 rapid recommendation update, and 13 further topics. 17 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/antibody-drug-conjugates"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Antibody-Drug conjugates

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Antibody-Drug Conjugates

<a id="topic-2.2.2.1.6-1"></a>

### Antibody-drug conjugate recommendations in third-line treatment and beyond: ESMO 2026 guideline

> “ChT or antibody–drug conjugates (ADCs) can be recommended for patients with tumours considered endocrine-resistant or refractory when targeted agents have already been used or ruled out due to lack of therapeutically relevant molecular alterations [V, B].”
> “Trastuzumab deruxtecan (T-DXd) is recommended for patients with HER2-low or -ultralow disease after at least two lines of ET for MBC (or after one line of ET if progression occurred within 24 months of adjuvant ET or within 6 months of ET–CDK4/6 inhibitor for MBC) [I, A; ESMO-MCBS v2.0 score: 3].”
> “Sacituzumab govitecan can be recommended for patients with ER-positive, HER2-negative MBC after at least one line of ChT [I, B; ESMO-MCBS v2.0 score: 4].”
> “Datopotamab deruxtecan (Dato-DXd) can also be recommended for patients with ER-positive, HER2-negative MBC who have received at least one prior line of ChT [I, B; ESMO-MCBS v2.0 score: 3].”
> “T-DXd is recommended for patients with HER2-low MBC after at least one line of ChT if not already used [I, A; ESMO-MCBS v2.0 score: 4].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.1.6-2"></a>

### Antibody-drug conjugate positioning and sequencing: ABC8 consensus 2026

> “In the ADC landscape, DESTINY-Breast06 showed that T-DXd can be an option for patients with HER2-low disease when the decision to initiate cytotoxic therapy is made, now earlier in the treatment sequence, as first-line cytotoxic therapy after progression on endocrine therapy and for whom further endocrine therapy was considered unsuitable, based on a 5.1-month improvement in median PFS over physician's choice chemotherapy (HR: 0.62), OS showed no statistically significant improvement”
> “For patients with HER2 ultra-low disease, the available data remain limited and further evidence is required before a recommendation can be made.”
> “In view of the modest PFS improvement, the absence of mature OS data, the side effect profile, and the availability of other treatment options, Dato-DXd in this setting is not a preferred option at present.”
> “Sacituzumab govitecan has moved to a less favored position in this subtype following the negative results of ASCENT-07, which failed to demonstrate superiority over single-agent chemotherapy as first-line cytotoxic therapy in ER+/HER2-negative ABC (median PFS by BICR: 8.3 months in both arms; HR: 0.85)”
> “In the absence of validated predictive biomarkers and robust evidence from prospective clinical trials, routine sequencing of ADCs in this setting cannot currently be recommended.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.6-3"></a>

### Trastuzumab deruxtecan for HER2-low disease: ASCO 2022 rapid recommendation update

> “Patients with HER2 IHC 1+ or 2+ and ISH-negative metastatic breast cancer who have received at least one prior chemotherapy for metastatic disease, and if hormone receptor–positive are refractory to endocrine therapy, should be offered treatment with trastuzumab deruxtecan (Type: evidence based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: strong).”

Source: [Moy et al. (2022)](https://ascopubs.org/doi/10.1200/JCO.22.01533)

<a id="topic-2.2.2.1.6-4"></a>

### Sacituzumab govitecan for hormone receptor-positive disease: ASCO 2023 rapid recommendation update

> “Patients with hormone receptor–positive HER2-negative metastatic breast cancer who are refractory to endocrine therapy and have received at least two prior lines of chemotherapy for metastatic disease may be offered SG.”
> “Key grade ≥ 3 treatment-related adverse events with SG were diarrhea (5%) and neutropenic complications including febrile neutropenia (4%) and neutropenic colitis (2%).”

Source: [Moy et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02807)

<a id="topic-2.2.2.1.6-5"></a>

### Comparator regulatory information: trastuzumab deruxtecan

> “Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting”
> “HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy”
> “Interstitial Lung Disease (ILD) and pneumonitis, including severe, life-threatening, and fatal cases, have been reported with ENHERTU.”

Source: [Enhertu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761139s041s043lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

### Comparator regulatory information: datopotamab deruxtecan

> “human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.”
> “In the pooled safety population [see Adverse Reactions (6.1)], ocular adverse reactions occurred in 38% of patients treated with DATROWAY.”
> “The most common (≥5%) ocular adverse reactions were dry eye (18%), keratitis (16%), increased lacrimation (6%), and conjunctivitis (5%).”

Source: [Datroway prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761394s003lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

### Comparator regulatory information: sacituzumab govitecan

> “TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.”
> “TRODELVY can cause severe, life-threatening, or fatal neutropenia.”
> “TRODELVY can cause severe diarrhea.”

Source: [Trodelvy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761115s064lbl.pdf)

<a id="topic-2.2.2.1.6-8"></a>

### Trastuzumab deruxtecan after chemotherapy in HER2-low disease: DESTINY-Breast04

> “Of 557 patients who underwent randomization, 494 (88.7%) had hormone receptor–positive disease and 63 (11.3%) had hormone receptor–negative disease.”
> “In the hormone receptor–positive cohort, the median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician’s choice group (hazard ratio for disease progression or death, 0.51; P<0.001) and overall survival was 23.9 months and 17.5 months, respectively (hazard ratio for death, 0.64; P=0.003).”
> “Among patients who had received previous treatment with CDK4/6 inhibitors, the median progression-free survival was 10.0 months in the trastuzumab deruxtecan group; without previous CDK4/6 inhibitor treatment, it was 11.7 months.”
> “Adjudicated, drug-related interstitial lung disease/pneumonitis occurred in 12.1% of the patients who received trastuzumab deruxtecan; 0.8% had grade 5 events.”

Source: [Modi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10561652/)

<a id="topic-2.2.2.1.6-9"></a>

### Trastuzumab deruxtecan in HER2-low disease: DESTINY-Breast04 long-term survival

> “For the HR+ cohort, the median OS was 23.9 months (95% CI 21.7–25.2) in the T-DXd arm and 17.6 months (95% CI 15.1–20.2) in the TPC arm (hazard ratio 0.69; 95% CI 0.55–0.87)”
> “Grade ≥3 TEAEs occurred in 202 patients (54.4%) in the T-DXd arm and in 116 patients (67.4%) in the TPC arm.”
> “The most common TEAEs associated with drug discontinuation were investigator-assessed interstitial lung disease (ILD) and/or pneumonitis at 10.2% in the T-DXd arm and peripheral sensory neuropathy at 2.3% in the TPC arm.”

Source: [Modi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705423/)

<a id="topic-2.2.2.1.6-10"></a>

### Trastuzumab deruxtecan after endocrine therapy in HER2-low or HER2-ultralow disease: DESTINY-Breast06

> “Of the 866 patients who underwent randomization, 713 had HER2-low disease, and 153 had HER2-ultralow disease.”
> “Among the patients with HER2-low disease, the median progression-free survival was 13.2 months (95% confidence interval [CI], 11.4 to 15.2) in the trastuzumab deruxtecan group and 8.1 months (95% CI, 7.0 to 9.0) in the chemotherapy group (hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75; P<0.001); the results were consistent in the exploratory HER2-ultralow population.”
> “Adverse events of grade 3 or higher occurred in 52.8% of the patients in the trastuzumab deruxtecan group and in 44.4% of those in the chemotherapy group.”
> “Adjudicated interstitial lung disease or pneumonitis occurred in 49 patients (11.3%; three events were grade 5 in severity) and in 1 patient (0.2%; grade 2), respectively.”

Source: [Bardia et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39282896/)

<a id="topic-2.2.2.1.6-11"></a>

### Trastuzumab deruxtecan by time to progression on first-line CDK4/6 inhibitor: DESTINY-Breast06 subgroup analysis

> “Median PFS (95% confidence interval) favored T-DXd versus TPC regardless of time to progression (TTP) on prior first-line endocrine therapy (ET) + cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i): <6 months: 14.0 (11.2-15.9) versus 6.5 (4.2-8.4) months for T-DXd versus TPC; 6-12 months: 13.2 (8.6-16.4) versus 6.9 (4.3-10.4) months; >12 months: 12.9 (9.8-17.1) versus 8.2 (6.9-10.9) months.”

Source: [Curigliano et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41780642/)

<a id="topic-2.2.2.1.6-12"></a>

### Trastuzumab deruxtecan after endocrine therapy: FDA approval summary

> “Random assignment was 1:1 to T-DXd or investigator's choice of chemotherapy (paclitaxel, nab-paclitaxel, or capecitabine).”
> “The trial also met its key secondary end point, PFS by BICR in the overall population, with a HR of 0.64 (95% CI, 0.54 to 0.76, P < .0001).”
> “This is the first indication specifying the category of HER2-ultralow expression in breast cancer, and an assay to select patients for this category was approved contemporaneously.”

Source: [Dilawari et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40763319/)

<a id="topic-2.2.2.1.6-13"></a>

### Datopotamab deruxtecan versus chemotherapy: TROPION-Breast01 progression-free survival and safety

> “Patients were randomly assigned to Dato-DXd (n = 365) or ICC (n = 367).”
> “The median PFS by BICR was 6.9 months (95% CI, 5.7 to 7.4) with Dato-DXd versus 4.9 months (95% CI, 4.2 to 5.5) with ICC.”
> “The rate of grade ≥3 treatment-related adverse events (TRAEs) with Dato-DXd was lower than ICC (20.8% v 44.7%).”
> “The most common TRAEs (any grade; grade ≥3) were nausea (51.1%; 1.4%) and stomatitis (50%; 6.4%) with Dato-DXd and neutropenia (grouped term, 42.5%; 30.8%) with ICC.”

Source: [Bardia et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11771365/)

<a id="topic-2.2.2.1.6-14"></a>

### Datopotamab deruxtecan versus chemotherapy: TROPION-Breast01 final overall survival

> “At data cut-off, median follow-up was 22.8 months.”
> “OS for the Dato-DXd versus ICC arm did not reach statistical significance (hazard ratio 1.01, 95% confidence interval 0.83-1.22, P = 0.9445).”
> “Use of ADCs (trastuzumab deruxtecan and sacituzumab govitecan) as subsequent therapy was imbalanced: 12.3% in the Dato-DXd arm versus 24.0% in the ICC arm.”

Source: [Pistilli et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41448362/)

<a id="topic-2.2.2.1.6-15"></a>

### Datopotamab deruxtecan: FDA approval summary

> “TB01 demonstrated a 2-month improvement in median PFS for Dato-DXd compared to ICC (6.9 months vs. 4.9 months, respectively; stratified hazard ratio (HR) 0.63 (95% CI: 0.52, 0.76; p<0.0001).”
> “The OS endpoint was not met; at the final analysis (FA) of OS, the median OS was 18.6 months in the Dato-DXd arm and 18.3 months in the ICC arm (HR: 1.01, 95% CI: 0.83, 1.22).”
> “The most commonly reported adverse reactions (≥20%) with Dato-DXd were stomatitis, nausea, fatigue, alopecia, constipation, dry eye, keratitis, and vomiting.”

Source: [Royce et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12393668/)

<a id="topic-2.2.2.1.6-16"></a>

### Sacituzumab govitecan versus chemotherapy: TROPiCS-02 progression-free survival

> “The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease.”
> “The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively.”
> “Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%).”

Source: [Rugo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36027558/)

<a id="topic-2.2.2.1.6-17"></a>

### Sacituzumab govitecan versus chemotherapy: TROPiCS-02 final overall survival

> “Overall survival was significantly improved with sacituzumab govitecan versus chemotherapy (median 14·4 months [95% CI 13·0-15·7] vs 11·2 months [10·1-12·7]; hazard ratio [HR] 0·79, 95% CI 0·65-0·96; p=0·020); survival benefit was consistent across Trop-2 expression-level subgroups.”
> “ORR was significantly improved with sacituzumab govitecan compared with chemotherapy (57 [21%] patients vs 38 [14%]; odds ratio 1·63 [95% CI 1·03-2·56]; p=0·035)”
> “One fatal adverse event (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.”

Source: [Rugo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37633306/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
